![Willy Wiyatno](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Perfil
Dr. Wiyatno joined Hercules Technology Capital Group in April 2006 focusing on the life science practice.
Prior to joining Hercules, he was a research scientist at Applied Biosystems (ABI) for four years where he focused on the development of emerging technologies in the areas of sample preparation, detection and analysis of DNA and proteins.
Willy is a lecturer at Stanford University and is currently pursuing his Chartered Financial Analyst accreditation.
He is an active board member of Golden Gate Polymer Forum (GGPF), a local non-profit organization dedicated to the advancement of materials and devices.
Willy obtained his Master and doctorate degrees in Chemical Engineering at Stanford University in 1999 and 2002, respectively.
He completed his bachelor degree at University of Wisconsin – Madison in 1997 in the area of Chemical Engineering.
Antiguos cargos conocidos de Willy Wiyatno.
| Empresas | Cargo | Fin |
|---|---|---|
Hercules Capital
 Hercules Capital Investment ManagersFinance Hercules Capital invests in public and private companies located in the United States. The firm focuses on technology and life science sectors. It participates in early, later, buyout and growth stage capital requirements in the form of debt and equity with investment size ranging from USD 5 to 500 million. | Analista de Capital Privado | 30/06/2007 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
10
Relaciones de 1er grado
1
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Hercules Capital
Hercules Capital Investment ManagersFinance Hercules Capital invests in public and private companies located in the United States. The firm focuses on technology and life science sectors. It participates in early, later, buyout and growth stage capital requirements in the form of debt and equity with investment size ranging from USD 5 to 500 million. | Finance |
- Bolsa de valores
- Insiders
- Willy Wiyatno
